TAIPEI, Taiwan, Dec. 23, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a global clinical-stage oncology company focused on developing novel cancer therapies such as antibody-drug conjugates (ADCs) and active immunotherapies (4174. TWO), and GlyTech, Inc. (GlyTech), a Japanese manufacturer specializing in glycan production and chemical glycosylation technologies, have entered into a commercialization agreement and a material transfer agreement.
Under the terms of the commercialization agreement, OBI grants GlyTech
the rights to commercialize and promote OBI’s GlycOBI® ADC enabling technologies, powered by EndoSymeOBI®, to potential pharmaceutical and biotech partners in Japan. GlyTech will also be a key supplier of glycans in Japan. Under the terms of the material transfer agreement, OBI will transfer certain of its advanced materials to GlyTech for research to advance the efficient production of glycans for ADCs.Heidi Wang, Ph.D., Managing Director of OBI Pharma, said, “GlyTech is one of our trusted suppliers for high-quality glycans. We are excited to collaborate with GlyTech to expand the reach of OBI’s novel GlycOBI® ADC enabling technologies to potential pharmaceutical and biotech partners in Japan. We also look forward to collaborative research with GlyTech, which is part of our plan to ensure scalable, high-quality glycan manufacturing and supply for ADCs.”
Hiroaki Asai, Chairman and CEO of GlyTech, added: “OBI Pharma’s innovative GlycOBI® ADC technologies are a testament to their mastery of enzyme-based precision synthetic organic chemistry. GlyTech, Inc. is pleased to support the contribution of GlycOBI® ADC technologies to the world as a supplier of highly pure human glycans, a key material for this technology. We look forward to OBI Pharma’s continued progress in developing new drugs.”
About OBI Pharma, Inc.
OBI Pharma, Inc. is a Taiwanese clinical-stage oncology company founded in 2002, with a mission to develop and license novel cancer therapeutic agents to address significant unmet medical needs in patients.
Using the Company’s proprietary ADC enabling technologies, including but not limited to GlycOBI® powered by EndoSymeOBI®, OBI has created its novel ADC pipeline, including OBI-992, OBI-902 and OBI-904, targeting TROP2 and nectin-4, respectively. In addition, the Company’s novel immuno-oncology pipeline targeting Globo H includes two active Globo H immunotherapy vaccines, adagloxad simolenin (formerly OBI-822) and OBI-833. OBI’s pipeline also includes a first-in-class small molecule prodrug targeting AKR1C3, OBI-3424, which selectively delivers a potent DNA alkylating anti-tumor agent in the presence of the enzyme aldo-keto reductase 1C3 (AKR1C3) which is highly expressed in tumors. For more information, visit www.obipharma.com .
GlycOBI® and EndoSymeOBI® are registered trademarks of OBI Pharma, Inc.
About GlyTech, Inc.
GlyTech, Inc. is headquartered in Kyoto, Japan and was founded in 2012 as the world's only life sciences company capable of commercially producing human-like glycans. Its mission is to contribute to the efforts to enable people to live healthier lives by contributing to the development of cutting-edge products and technologies that leverage glycans, proteins, nucleotides and other natural biochemicals.
GlyTech’s technology platforms include glycan enhancement of drugs across multiple modalities, brain drug delivery technology and peptide linker discovery services. GlyTech’s proprietary pipeline includes several glycan-enabled assets and the Company is conducting investigator-initiated (P2a) clinical trials of a glycosylated somatostatin with acromegaly as the target indication.
For more information, visit www.glycech-inc.com/
COMPANY CONTACT:
Kevin Poulos
Director of Business Development
OBI Pharma, Inc.
1.619.537.7698 ext. 102
kpoulos@obipharmausa.com
http://www.obipharma.com/
https://www.linkedin.com/company/obi-pharma-inc
https://twitter.com/obipharma?lang=en
No comments:
Post a Comment